Helen Frankenthaler Foundation

Cardiovascular Drug Raw Material

Journal of Cardiovascular Pharmacology Latest Articles

Latest Articles

The editors of this journal are pleased to offer electronic publication of accepted papers prior to issue publication. These papers can be cited using the date of access and the unique DOI number. Any final changes in manuscripts will be made at the time of issue publication and will be reflected in the final electronic version of the issue.

Disclaimer: Articles appearing in this Latest Articles section have been peer-reviewed and accepted for publication in this journal and posted online before issue publication. Articles appearing here may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Accordingly, Wolters Kluwer, the editors and authors and their respective employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained the articles in this section.

Original Article: VASCULAR

Sphingosine-1-Phosphate/Protein Kinase Cβ2 Signaling Mediates Hypercontraction of Mesenteric Arterial Smooth Muscle in Spontaneously Hypertensive Rats

Wang, Haiyan; Deng, Libing; Shan, Yu; Wang, Aizhong; Zhang, Hui; Wang, Yan

March 03, 2026

Plain Language Summary

This study explores the role of protein kinase C beta 2 (PKCβ2) in hypertension-related vascular issues, focusing on mesenteric arteries in spontaneously hypertensive rats (SHR). Researchers found that PKCβ2 expression was elevated in SHR, and S1P significantly increased PKCβ2 phosphorylation, contributing to artery hypercontraction. Sphingosine 1-phosphate (S1P) was shown to activate PKCβ2 through its receptors S1P2 and S1P3, enhancing calcium sensitization and contraction. Inhibiting PKCβ2 reduced norepinephrine and S1P-induced contraction, suggesting that the S1P/PKCβ2 pathway could be a target for treating hypertensive vascular dysfunction. This highlights the potential for new therapeutic strategies in managing hypertension.

Text is machine generated and may contain inaccuracies.

Original Article: CARDIAC

Cardioprotective effects of prophylactic ACE inhibitors in anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized trials

Pizzi, D.; Fazzini, L.; Bassil, D.; Bajaj, P.; Pugliesi, Gm.; Dessalvi, C. Cadeddu

March 03, 2026

Plain Language Summary

This study reviewed seven randomized controlled trials involving 686 patients to assess if angiotensin-converting enzyme inhibitors (ACEi) can prevent heart damage in those receiving anthracycline-based chemotherapy, commonly used for breast cancer. Half of the patients received ACEi as a preventive measure. Results showed that ACEi helped reduce the decline in heart function, specifically left ventricular ejection fraction (LVEF), especially in patients also treated with trastuzumab. However, ACEi did not significantly affect other heart function measures or troponin levels. Further research with larger sample sizes and longer follow-up is needed to confirm these findings.

Text is machine generated and may contain inaccuracies.

Commentary: CARDIAC

The more the lipid lowering agents, the merrier: welcome to combination therapy with cholesteryl ester transfer protein inhibitors!

Frati, Giacomo; Peruzzi, Mariangela; Giordano, Salvatore; Biondi-Zoccai, Giuseppe

March 02, 2026

Review Article: CARDIAC

The Multifaceted Role of Angiopoietin-Like Proteins in Coronary Heart Disease: From Molecular Mechanisms to Clinical Translation

Tan, Jie; Gu, Jun

March 02, 2026

Plain Language Summary

Coronary heart disease (CHD) is a major global health issue, and recent research has focused on angiotensin-like proteins (ANGPTLs) due to their role in lipid metabolism and inflammation. ANGPTLs are glycoproteins that regulate lipid levels by affecting lipoprotein lipase activity, and their dysfunction can lead to dyslipidemia and atherosclerosis. They also contribute to inflammation, worsening CHD. Current therapies targeting ANGPTLs, like monoclonal antibodies and small interfering RNA, are in clinical trials and show promise in safely lowering lipid levels. This study reviews ANGPTLs' role in CHD and highlights the potential of ANGPTL-targeted treatments for prevention and therapy.

Text is machine generated and may contain inaccuracies.

Original Article: CARDIAC

Diurnal rhythm in blood pressure is preserved in hypertensive mice despite therapy with mineralocorticoid receptor antagonists

Usai, Diana S; Kudryavtseva, Olga; Thomsen, Morten B

February 27, 2026

Plain Language Summary

This study explored how hypertension affects the natural daily cycle of blood pressure in mice, specifically whether it leads to a "non-dipper" phenotype, where the usual nighttime drop in blood pressure is reduced. Researchers induced hypertension in mice using L-NAME and monitored their blood pressure continuously. Initially, most mice showed a normal dipping pattern, but after hypertension was induced, only 42% maintained this pattern. The study also tested three mineralocorticoid receptor antagonists (MRAs) to see if they could restore the dipping pattern. Results showed that these MRAs did not affect the 24-hour blood pressure cycle or restore the dipping phenotype in hypertensive mice.

Text is machine generated and may contain inaccuracies.

Clinical Research (Not Trial): VASCULAR

Patients’ and Healthcare Professionals’ Perspectives in Managing Atherosclerotic Cardiovascular Disease: A Survey of Unmet Needs and Perceived Benefits of Treating Systemic Inflammation in Cardiovascular Diseases

Weber, Brittany; McCarty, Delilah; Robar, Carey; Fainberg, Udi; Fudim, Marat; Byrne, Katherine; Gluckman, Ty J.

February 25, 2026